Research Use Only. All compounds discussed are intended strictly for laboratory and scientific research. Not for human consumption or therapeutic application.
Overview: The GLP Peptide Landscape in 2026
The GLP receptor agonist family has become one of the most studied areas in metabolic research. Three generations of compounds now exist for laboratory investigation — each targeting a different combination of metabolic receptors. Understanding the mechanistic differences between Semaglutide, Tirzepatide, and GLP-3 (Retatrutide) is essential for designing effective preclinical research protocols.
Receptor Targeting: The Core Difference
The fundamental distinction between these three compounds is which receptors they activate:
- Semaglutide — GLP-1 receptor agonist only (single agonist)
- Tirzepatide — GLP-1 + GIP dual receptor agonist
- GLP-3 / Retatrutide — GLP-1 + GIP + Glucagon triple receptor agonist
Each additional receptor target introduces a new metabolic pathway into the research model, which is why the compounds show progressively different outcomes in preclinical and clinical studies.
Semaglutide in Research
Semaglutide is a GLP-1 receptor agonist that has been studied extensively for its effects on insulin secretion, glucagon suppression, gastric emptying, and appetite regulation. In clinical trials, semaglutide has demonstrated approximately 15-17% mean body weight reduction at maximum doses. It remains the most well-characterized GLP peptide in the research literature, making it a strong baseline comparator for newer compounds.
Key research applications: GLP-1 receptor pharmacology, insulin secretion models, appetite signaling, gastric motility studies.
Available at Peppy University: Semaglutide 5mg and 10mg
Tirzepatide in Research
Tirzepatide adds GIP receptor agonism to the GLP-1 framework. The GIP receptor component contributes enhanced insulin response and adipose tissue signaling that GLP-1 alone does not produce. Clinical trials showed approximately 20-22% mean body weight reduction — meaningfully higher than semaglutide — attributed in part to the complementary GIP pathway.
Key research applications: Dual receptor agonism studies, comparative GLP-1 vs GIP pathway investigation, insulin sensitivity models, adipose tissue metabolism research.
Available at Peppy University: Tirzepatide 10mg and 30mg
GLP-3 (Retatrutide) in Research
GLP-3 — Peppy University’s research designation for Retatrutide — adds the glucagon receptor as the third target. The glucagon receptor component increases energy expenditure and drives hepatic fat oxidation, mechanisms not activated by either semaglutide or tirzepatide. Phase 2 JAMA data showed approximately 24.2% mean body weight reduction at 48 weeks on the highest studied dose, with no plateau observed through the full study duration.
Key research applications: Triple receptor agonism studies, hepatic fat oxidation models, energy expenditure research, comparative single vs dual vs triple agonist protocols.
Available at Peppy University: GLP-3 10mg and GLP-3 30mg
Side-by-Side Research Comparison
| Compound | Receptors Targeted | Phase 2/3 Weight Reduction | Unique Research Value |
|---|---|---|---|
| Semaglutide | GLP-1 | ~15-17% | Most characterized baseline; GLP-1 pharmacology gold standard |
| Tirzepatide | GLP-1 + GIP | ~20-22% | GIP pathway contribution; dual agonist comparative studies |
| GLP-3 (Retatrutide) | GLP-1 + GIP + Glucagon | ~24.2% | Glucagon receptor addition; hepatic fat; energy expenditure models |
Which Compound for Your Research Protocol?
The choice depends on your research endpoints:
- GLP-1 receptor pharmacology → Semaglutide is the established reference compound
- Dual agonist or GIP pathway studies → Tirzepatide adds the GIP variable
- Triple agonism, glucagon pathway, or maximum metabolic effect studies → GLP-3 (Retatrutide) targets all three receptors
- Comparative studies across all three generations → Peppy University carries all three compounds for side-by-side protocol design
All compounds are available individually or as part of the Metabolic Stack at Peppy University.
All products at Peppy University are intended strictly for laboratory and scientific research purposes only. Not for human consumption. Research Use Only. Information presented references published peer-reviewed literature and is not medical advice.
Leave a Reply